Verona Pharma plc
VRNADelisted Oct 7, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001657312
Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.
Superinvestors holding VRNA, Q3 2025
2 superinvestors report holding Verona Pharma plc on Form 13F, worth $137.4M in total. Weight is Verona Pharma plc's share of each 13F portfolio; actions compare shares with Q2 2025.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Duquesne Family OfficeStanley Druckenmiller | 2.7% | 1,002,080 | $106.9M | Unchanged |
| Soros Fund ManagementGeorge Soros | 0.5% | 285,185 | $30.4M | New |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of VRNA each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q3 2025
2 superinvestors holding at quarter end
- New
- Soros Fund Management
- Sold out
- Maverick Capital
Q2 2025
2 superinvestors holding at quarter end
- Reduced
- Maverick Capital (−70.7%)
Q1 2025
2 superinvestors holding at quarter end
- Added
- Duquesne Family Office (+12.9%)
- Reduced
- Maverick Capital (−43.0%)
Q4 2024
2 superinvestors holding at quarter end
- Added
- Duquesne Family Office (+29.4%)
- Reduced
- Maverick Capital (−25.8%)
Q3 2024
2 superinvestors holding at quarter end
- New
- Duquesne Family Office
- Added
- Maverick Capital (+36.3%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+74.2%)
Q1 2024
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+7.2%)
Q4 2023
1 superinvestor holding at quarter end